Clinical trial
Pixantrone (BBR 2778) in Patients With Refractory Acute Myelogenous Leukemia…
NCT00106600 · CTI BioPharma, Industry · Completed
Key facts
| NCT number | NCT00106600 |
|---|---|
| Title | Pixantrone (BBR 2778) in Patients With Refractory Acute Myelogenous Leukemia (AML) |
| Official title | A Phase I/II Study of Pixantrone (BBR 2778) in Patients With Refractory Acute Myelogenous Leukemia (AML) |
| Lead sponsor | CTI BioPharma, Industry |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Acute Myelogenous Leukemia |
| Intervention type | Drug |
| Interventions | Pixantrone IV infusion |
| Enrollment | 12 |
| Start date | Mar 1, 2005 |
| Completion | Mar 1, 2007 |
| First posted | Mar 29, 2005 |
| Last update posted | Sep 18, 2023 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: